The U.S. Supreme Court’s decision to take up a case involving steep Medicare Part B payment cuts to 340B hospital-operated outpatient sites took many legal experts by surprise. However, attorneys that 340B Report conferred with believe the court will be
…
In addition to agreeing to review 340B hospitals’ four-year challenge to deep Medicare Part B cuts, the U.S. Supreme Court said last week that it will take up a case that could impact the calculation used to determine hospital eligibility
…
The U.S. Supreme Court this morning agreed to review a federal appeals court’s July 2020 ruling upholding a nearly 30% reduction in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.
The court’s decision to hear American Hospital Association (AHA)
…
Drug manufacturer Boehringer Ingelheim (BI) announced yesterday that it will stop shipping 340B-purchased drugs to hospitals’ contract pharmacies, effective Aug. 1.
Community health centers, HIV/AIDS clinics, and other federal grantee covered entities are exempt from BI’s new policy. It applies
…
A federal district judge in Delaware yesterday rejected the U.S. Health and Human Services Department’s (HHS) position that its withdrawal of its December 2020 advisory opinion on 340B contract pharmacy rendered drug manufacturer AstraZeneca’s claims against the opinion moot.
In
…
More than 150 hospitals have sued the U.S. Department of Health and Human Services (HHS) in the latest attempt by providers to end steep cuts in 340B reimbursement at their off-campus outpatient sites.
Filed in district court in Washington, D.C.,
…
Drug manufacturer Pfizer last week cited a federal judge’s June 16 opinion in AstraZeneca’s 340B contract pharmacy lawsuit in Pfizer’s own lawsuit aimed at striking down federal restrictions on manufacturer copay assistance to Medicare beneficiaries.
Pfizer sued the U.S. Health
…
Sixteen states have passed laws since 2019 addressing pharmacy benefit manager (PBM) discrimination against 340B covered entities, according to a draft summary of state action on the subject circulating among community health center advocates.
Meanwhile, two longtime 340B program policy
…
The U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) posted a notice yesterday about changes to the covered entity registration and manufacturer pricing components of 340B OPAIS, the 340B program database.
Today is the first day
…
On May 17, the federal government told six drug companies that their 340B contract pharmacy policies were illegal, and it asked them to provide updates by June 1 on their plans to comply with the law.
At least three of
…*Sign up for news summaries and alerts from 340B Report